Axsome Therapeutics Stock Investor Sentiment
| AXSM Stock | USD 97.74 1.08 1.09% |
About 57% of Axsome Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Axsome Therapeutics stock suggests that many investors are alarmed at this time. Axsome Therapeutics' investing sentiment overview a quick insight into current market opportunities from investing in Axsome Therapeutics. Many technical investors use Axsome Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Panic Vs Confidence
43
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Axsome Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Axsome Therapeutics.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Axsome Historical Sentiment
Although Axsome Therapeutics' investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Axsome, such as negative comments on social media and news outlets, may cause fear in the market and push Axsome Therapeutics' investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Axsome.
Axsome |
Axsome Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Axsome Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Axsome Therapeutics that are available to investors today. That information is available publicly through Axsome media outlets and privately through word of mouth or via Axsome internal channels. However, regardless of the origin, that massive amount of Axsome data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Axsome Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Axsome Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Axsome Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Axsome Therapeutics alpha.
Axsome Therapeutics Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Acquisition by Pizzie Nick of 36086 shares of Axsome Therapeutics at 65.02 subject to Rule 16b-3 | 10/04/2024 |
2 | Insider Trading | 10/14/2024 |
3 | Earnings call Axsome Therapeutics reports record quarterly revenue | 11/12/2024 |
4 | Axsome stock price target increased, rating held on strong sales | 11/13/2024 |
5 | RTW INVESTMENTS, LP Expands Stake in Madrigal Pharmaceuticals Inc | 11/14/2024 |
6 | Disposition of 33410 shares by Coleman Mark of Axsome Therapeutics at 5.94 subject to Rule 16b-3 | 11/19/2024 |
7 | Acquisition by Coleman Mark of 500 shares of Axsome Therapeutics at 58.15 subject to Rule 16b-3 | 11/22/2024 |
8 | Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy | 11/26/2024 |
9 | Mizuho raises Axsome shares target, rating held on new opportunities | 12/03/2024 |
Check out Axsome Therapeutics Hype Analysis, Axsome Therapeutics Correlation and Axsome Therapeutics Performance. To learn how to invest in Axsome Stock, please use our How to Invest in Axsome Therapeutics guide.You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Therapeutics. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.58) | Revenue Per Share 7.108 | Quarterly Revenue Growth 0.813 | Return On Assets (0.26) | Return On Equity (1.72) |
The market value of Axsome Therapeutics is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Axsome Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Therapeutics' market value can be influenced by many factors that don't directly affect Axsome Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Axsome Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.